New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci

Vaccine

Volumn 29, Issue 46, 2011, Pages 8175-8178

  Dale, James B ^a,b   Penfound, Thomas A ^a,b   Chiang, Edna Y ^a,b   Walton, William J ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Group a streptococci; M protein; Vaccine

Indexed keywords

30 VALENT VACCINE; BACTERIUM ANTIBODY; CROSS REACTING ANTIBODY; M PROTEIN; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; BACTERICIDAL ACTIVITY; BRAIN; CROSS REACTION; HEART; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; KIDNEY; NONHUMAN; PRIORITY JOURNAL; RABBIT; SEROTYPE; STREPTOCOCCUS GROUP A;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BLOOD BACTERICIDAL ACTIVITY; CARRIER PROTEINS; CROSS REACTIONS; OPSONIN PROTEINS; RABBITS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; VACCINES, SYNTHETIC;

EID: 80053951774     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.005     Document Type: Article

References (15)

1. Steer A.C., Batzloff M.R., Mulholland K., Carapetis J.R. Group A streptococcal vaccines: facts versus fantasy. Curr Opin Infect Dis 2009, 22(6):544-552.
2. Kotloff K.L., Corretti M., Palmer K., Campbell J.D., Reddish M.A., Hu M.C., et al. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA 2004, 292(6):709-715.
3. McNeil S.A., Halperin S.A., Langley J.M., Smith B., Warren A., Sharratt G.P., et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005, 41(8):1114-1122.
4. Dale J.B. Current status of group A streptococcal vaccine development. Adv Exp Med Biol 2008, 609:53-63.
5. Dale J.B. Multivalent group A streptococcal vaccines. Inf Dis Clin N Amer 1999, 13:227-243.
6. Hu M., Walls M., Stroop S., Reddish M., Beall B., Dale J. Immunogenicity of a 26-valent group a streptococcal vaccine. Infect Immun 2002, 70:2171-2177.
7. Shulman S.T., Tanz R.R., Kabat W., Kabat K., Cederlund E., Patel D., et al. Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002. Clin Infect Dis 2004, 39(3):325-332.
8. Shulman S.T., Tanz R.R., Dale J.B., Beall B., Kabat W., Kabat K., et al. Seven-year surveillance of north American pediatric group a streptococcal pharyngitis isolates. Clin Infect Dis 2009, 49(1):78-84.
9. O'Loughlin R.E., Roberson A., Cieslak P.R., Lynfield R., Gershman K., Craig A., et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007, 45(7):853-862.
10. Luca-Harari B., Darenberg J., Neal S., Siljander T., Strakova L., Tanna A., et al. Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2009, 47(4):1155-1165.
11. Steer A.C., Law I., Matatolu L., Beall B.W., Carapetis J.R. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 2009, 9(10):611-616.
12. Shulman S.T., Stollerman G., Beall B., Dale J.B., Tanz R.R. Temporal changes in streptococcal M protein types and the near-disappearance of acute rheumatic fever in the United States. Clin Infect Dis 2006, 42(4):441-447.
13. Dale J.B., Chiang E.Y., Liu S.Y., Courtney H.S., Hasty D.L. New protective antigen of group A streptococci. J Clin Invest 1999, 103:1261-1268.
14. Dale J.B. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. Vaccine 1999, 17:193-200.
15. Carapetis J.R., Steer A.C., Mulholland E.K., Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005, 5(11):685-694.